STOKStoke Therapeutics, Inc.

1. Sep 25, 2026On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026.Director or officer change · Form 8-K
2. Aug 3, 2026As previously disclosed, on May 20, 2022, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company may offer and sell shares (“Placement Shares”) of …Other event · Form 8-K
3. Aug 3, 2026Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
4. Jun 30, 2026As noted in the Press Release, enrollment of 162 patients into the EMPEROR study has now completed in the planned primary analysis population across the U.S., U.K., and Japan.Regulation FD disclosure · Form 8-K
5. May 7, 2026Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
6. Apr 7, 2026On April 3, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (“Stoke” or the “Company”), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board …Director or officer change · Form 8-K
7. Mar 27, 2026The reports of KPMG on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.Auditor change · Form 8-K
8. Mar 3, 2026On February 13, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer (the “Bonus”)Director or officer change · Form 8-K
9. Jan 26, 2026On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agreement”), in order to expand its office and laboratory space.Material agreement entered · Form 8-K
10. Jan 12, 2026The Press Release provides an update related to the design of the Company’s Phase 3 clinical trial of zorevunersen, including the following: Phase 3 Study of Zorevunersen • The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that is anticipated to …Earnings release · Form 8-K
11. Dec 5, 2025As noted in the Press Release, the Company and Biogen presented data at the AES Annual Meeting that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome, including the following: Propensity Score Weighted Analysis • Long-term …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.